Fluoroquinolone-Associated Myasthenia Gravis Exacerbation: Evaluation of Postmarketing Reports from the US FDA Adverse Event Reporting System and a Literature Review

By Jones S. Christopher   Sorbello Alfred   Boucher Robert M.  

Drug Safety, Vol. 34, Iss. 10, 2011-10 ,pp. : 839-847

Adis International

Access to resources Recommend Favorite

An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database

By Wang Hsin-wei  

Drug Safety, Vol. 33, Iss. 12, 2010-12 ,pp. : 1117-1133

Adis International

Access to resources Recommend Favorite

Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database: A Disproportionality Analysis

By Shamloo Behrooz K.  

Drug Safety, Vol. 35, Iss. 6, 2012-06 ,pp. : 507-518

Adis International

Access to resources Recommend Favorite

Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database

By Motola Domenico  

Drug Safety, Vol. 35, Iss. 4, 2012-04 ,pp. : 315-323

Adis International

Access to resources Recommend Favorite

Drug-versus-Drug Adverse Event Rate Comparisons: A Pilot Study Based on Data from the US FDA Adverse Event Reporting System

By Hochberg Alan M.   Pearson Ronald K.   O'Hara Donald J.   Reisinger Stephanie J.  

Drug Safety, Vol. 32, Iss. 2, 2009-01 ,pp. : 137-146

Adis International

Access to resources Recommend Favorite